Tags

Type your tag names separated by a space and hit enter

Circulating 25-Hydroxyvitamin D Concentration and Risk of Breast, Prostate, and Colorectal Cancers: The Melbourne Collaborative Cohort Study.
Cancer Epidemiol Biomarkers Prev. 2019 05; 28(5):900-908.CE

Abstract

BACKGROUND

The role of vitamin D in cancer risk remains controversial, and limited data exist on associations between vitamin D and subtypes of specific cancers. We investigated associations between circulating 25-hydroxyvitamin D (25(OH)D) and risk of colorectal, breast, and prostate cancers, including subtypes.

METHODS

A case-cohort study within the Melbourne Collaborative Cohort Study included 547 colorectal, 634 breast, and 824 prostate cancers, and a sex-stratified random sample of participants (n = 2,996). Concentration of 25(OH)D in baseline-dried blood spots was measured using LC-MS/MS. Cox regression yielded adjusted HRs and 95% confidence intervals (CI) for each cancer in relation to plasma-equivalent 25(OH)D concentration. Associations by stage and BRAF/KRAS status for colorectal cancer, estrogen receptor status for breast cancer, and aggressiveness for prostate cancer were examined in competing risks models.

RESULTS

25(OH)D concentrations were inversely associated with risk of colorectal cancer [highest vs. lowest 25(OH)D quintile: HR, 0.71; 95% confidence interval (CI), 0.51-0.98], which was limited to women (HR, 0.52; 95% CI, 0.33-0.82). Circulating 25(OH)D was also inversely associated with BRAF V600E-positive colorectal cancer (per 25 nmol/L increment: HR, 0.71; 95% CI, 0.50-1.01). There were no inverse associations with breast cancer (HR, 0.98; 95% CI, 0.70-1.36) or prostate cancer (HR, 1.11; 95% CI, 0.82-1.48).

CONCLUSIONS

Circulating 25(OH)D concentration was inversely associated with colorectal cancer risk for women, but not with risk of breast cancer or prostate cancer.

IMPACT

Vitamin D might play a role in preventing colorectal cancer. Further studies are required to confirm whether vitamin D is associated with specific tumor subtypes.

Links

FREE Publisher Full Text

Authors+Show Affiliations

Heath AK
Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia. Cancer Epidemiology and Intelligence Division, Cancer Council Victoria, Melbourne, Victoria, Australia. School of Public Health, Imperial College London, London, United Kingdom.
Hodge AM
Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia. Cancer Epidemiology and Intelligence Division, Cancer Council Victoria, Melbourne, Victoria, Australia.
Ebeling PR
Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.
Eyles DW
Queensland Brain Institute, University of Queensland, St Lucia, Queensland, Australia. Queensland Centre for Mental Health Research, The Park Centre for Mental Health, Wacol, Queensland, Australia.
Kvaskoff D
Queensland Brain Institute, University of Queensland, St Lucia, Queensland, Australia.
Buchanan DD
Colorectal Oncogenomics Group, Department of Clinical Pathology, University of Melbourne, Victorian Comprehensive Cancer Centre, Melbourne, Victoria, Australia. University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Melbourne, Victoria, Australia. Genomic Medicine and Family Cancer Clinic, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Giles GG
Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia. Cancer Epidemiology and Intelligence Division, Cancer Council Victoria, Melbourne, Victoria, Australia.
Williamson EJ
Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia. Cancer Epidemiology and Intelligence Division, Cancer Council Victoria, Melbourne, Victoria, Australia. Farr Institute of Health Informatics Research, London, United Kingdom. Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom.
English DR
Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia. d.english@unimelb.edu.au. Cancer Epidemiology and Intelligence Division, Cancer Council Victoria, Melbourne, Victoria, Australia.

MeSH

AdultAgedAustraliaBiomarkers, TumorBreast NeoplasmsCase-Control StudiesColorectal NeoplasmsFemaleFollow-Up StudiesHumansIncidenceMaleMiddle AgedPrognosisProspective StudiesProstatic NeoplasmsRisk FactorsVitamin D

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

30842127

Citation

Heath, Alicia K., et al. "Circulating 25-Hydroxyvitamin D Concentration and Risk of Breast, Prostate, and Colorectal Cancers: the Melbourne Collaborative Cohort Study." Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, vol. 28, no. 5, 2019, pp. 900-908.
Heath AK, Hodge AM, Ebeling PR, et al. Circulating 25-Hydroxyvitamin D Concentration and Risk of Breast, Prostate, and Colorectal Cancers: The Melbourne Collaborative Cohort Study. Cancer Epidemiol Biomarkers Prev. 2019;28(5):900-908.
Heath, A. K., Hodge, A. M., Ebeling, P. R., Eyles, D. W., Kvaskoff, D., Buchanan, D. D., Giles, G. G., Williamson, E. J., & English, D. R. (2019). Circulating 25-Hydroxyvitamin D Concentration and Risk of Breast, Prostate, and Colorectal Cancers: The Melbourne Collaborative Cohort Study. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, 28(5), 900-908. https://doi.org/10.1158/1055-9965.EPI-18-1155
Heath AK, et al. Circulating 25-Hydroxyvitamin D Concentration and Risk of Breast, Prostate, and Colorectal Cancers: the Melbourne Collaborative Cohort Study. Cancer Epidemiol Biomarkers Prev. 2019;28(5):900-908. PubMed PMID: 30842127.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Circulating 25-Hydroxyvitamin D Concentration and Risk of Breast, Prostate, and Colorectal Cancers: The Melbourne Collaborative Cohort Study. AU - Heath,Alicia K, AU - Hodge,Allison M, AU - Ebeling,Peter R, AU - Eyles,Darryl W, AU - Kvaskoff,David, AU - Buchanan,Daniel D, AU - Giles,Graham G, AU - Williamson,Elizabeth J, AU - English,Dallas R, Y1 - 2019/03/06/ PY - 2018/10/26/received PY - 2018/12/19/revised PY - 2019/02/26/accepted PY - 2019/3/8/pubmed PY - 2020/7/17/medline PY - 2019/3/8/entrez SP - 900 EP - 908 JF - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology JO - Cancer Epidemiol Biomarkers Prev VL - 28 IS - 5 N2 - BACKGROUND: The role of vitamin D in cancer risk remains controversial, and limited data exist on associations between vitamin D and subtypes of specific cancers. We investigated associations between circulating 25-hydroxyvitamin D (25(OH)D) and risk of colorectal, breast, and prostate cancers, including subtypes. METHODS: A case-cohort study within the Melbourne Collaborative Cohort Study included 547 colorectal, 634 breast, and 824 prostate cancers, and a sex-stratified random sample of participants (n = 2,996). Concentration of 25(OH)D in baseline-dried blood spots was measured using LC-MS/MS. Cox regression yielded adjusted HRs and 95% confidence intervals (CI) for each cancer in relation to plasma-equivalent 25(OH)D concentration. Associations by stage and BRAF/KRAS status for colorectal cancer, estrogen receptor status for breast cancer, and aggressiveness for prostate cancer were examined in competing risks models. RESULTS: 25(OH)D concentrations were inversely associated with risk of colorectal cancer [highest vs. lowest 25(OH)D quintile: HR, 0.71; 95% confidence interval (CI), 0.51-0.98], which was limited to women (HR, 0.52; 95% CI, 0.33-0.82). Circulating 25(OH)D was also inversely associated with BRAF V600E-positive colorectal cancer (per 25 nmol/L increment: HR, 0.71; 95% CI, 0.50-1.01). There were no inverse associations with breast cancer (HR, 0.98; 95% CI, 0.70-1.36) or prostate cancer (HR, 1.11; 95% CI, 0.82-1.48). CONCLUSIONS: Circulating 25(OH)D concentration was inversely associated with colorectal cancer risk for women, but not with risk of breast cancer or prostate cancer. IMPACT: Vitamin D might play a role in preventing colorectal cancer. Further studies are required to confirm whether vitamin D is associated with specific tumor subtypes. SN - 1538-7755 UR - https://www.unboundmedicine.com/medline/citation/30842127/Circulating_25_Hydroxyvitamin_D_Concentration_and_Risk_of_Breast_Prostate_and_Colorectal_Cancers:_The_Melbourne_Collaborative_Cohort_Study_ L2 - http://cebp.aacrjournals.org/cgi/pmidlookup?view=long&pmid=30842127 DB - PRIME DP - Unbound Medicine ER -